Author:
Nakamura K,Yamaguchi T,Ishihara T,Sudo K,Kato H,Saisho H
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Bruckner H, Zhou G, Haenel P (1998) Ex vivo ATP tumor testing of gemcitabine for combination chemotherapy and biochemical modulation. Proc Am Assoc Cancer Res 89: 310 (abstract 2116)
2. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
3. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P (2003) Phase II trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264–1270
4. Evans D, Abbruzzese J, Rich T (1997) Cancer of the pancreas. In Cancer: Principles and Practice of Oncology, De Vita VJ, Hellman S, Rosenberg S (eds) pp 1054–1077. Philadelphia, PA: Lippincott
5. Feliu J, Lopez Alvarez MP, Jaraiz MA, Constenla M, Vicent JM, Belon J, Lopez Gomez L, de Castro J, Dorta J, Gonzalez Baron M (2000) Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma. The ONCOPAZ Cooperative Group. Cancer 89: 1706–1713
Cited by
112 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献